Explanipedia

Targeted cardiovascular risk screening through an SMS programme (Text to Detect) in general practice: a three-arm, parallel group, randomised controlled trial Open

Natalie Raffoul, Kerryn Brims, Adam J. Nelson, Atef Asham, Carissa Bonner · 2025

Will Dynamic Evaluation of Cardiogenic Shock Using Machine Learning Models Lead to Improved Survival? Open

Vishal Goel, William Chan, Jack Wei Chieh Tan, Sidney Lo, Adam J. Nelson , et al. · 2025

Cardiogenic shock (CS) is characterised by tissue hypoxia as a result of circulatory failure arising from inadequate cardiac output and is commonly a complication of acute myocardial infarction (AMI). Despite improvement in reperfusion str…

Hypertriglyceridaemia: A practical approach for primary care Open

N. Lan, Adam J. Nelson, Tom Brett, Charlotte Hespe, Gerald F. Watts , et al. · 2025

Hypertriglyceridaemia is often attributable to secondary causes, which should be identified and addressed. Healthy lifestyle modifications targeting diet, exercise, alcohol consumption and weight are fundamental. Statins should be prescrib…

SAFETY AND EFFICACY OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION: FROM GENETICS TO OUTCOME TRIALS Open

John J.P. Kastelein, Brian A. Ference, Adam J. Nelson, Stephen C. Nicholls, Kausik K Ray · 2025

SAFETY AND EFFICACY OF OBICETRAPIB IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA Open

Andrew Hsieh, Stephen C. Nicholls, Adam J. Nelson, Marc Ditmarsch, John J.P. Kastelein , et al. · 2025

Prevalence of Overweight and Obesity Among Patients Admitted With Acute Coronary Syndromes: Implications for Semaglutide Eligibility to Further Reduce Residual Risk Open

Matthew Lim, M. Allahwala, Andrew Booth, Shaun Evans, David Jesudason , et al. · 2025

IMPACT OF THE CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR, OBICETRAPIB, ON LIPOPROTEIN(A) LEVELS: POOLED DATA FROM PHASE 3 CLINICAL TRIALS Open

Andrew Hsieh, Stephen J. Nicholls, Kausik K Ray, Michael Szarek, Marc Ditmarsch , et al. · 2025

Type 2 Diabetes and Acute Myocardial Infarction: Admission Complexity and Readmission Rates Open

M. Allahwala, Andrew Booth, Adam J. Nelson, Chinmay S. Marathe, J. Marathe , et al. · 2025

SAFETY AND EFFICACY OF OBICETRAPIB IN PATIENTS AT HIGH CARDIOVASCULAR RISK Open

Andrew Hsieh, Stephen J Nicholls, Adam J. Nelson, Marc Ditmarsch, John J.P. Kastelein , et al. · 2025

EFFECT OF OBICETRAPIB ON NEW ONSET DIABETES IN PATIENTS WITH ELEVATED LDL-C RECEIVING MAXIMALLY TOLERATED STATIN THERAPY: POOLED ANALYSES OF THE BROADWAY AND BROOKLYN TRIALS Open

John J.P. Kastelein, Kausik K Ray, Michael Szarek, Adam J. Nelson, Marc Ditmarsch , et al. · 2025

Characteristics of patients prescribed SGLT-2i and/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-diabetes trial Open

Adam J. Nelson, Lisa A. Kaltenbach, Hussein R. Al‐Khalidi, Monica Leyva, Laura Webb , et al. · 2025

Colchicine in Atherosclerotic Cardiovascular Disease – Weighing up the evidence so far Open

Mau T. Nguyen, Adam J. Nelson, Peter J. Psaltis · 2025

Current perspectives on Lp(a)-lowering therapies: Who may benefit? Open

Stephen J. Nicholls, Adam J. Nelson · 2025

Increasing evidence has implicated lipoprotein(a) [Lp(a)] in the pathogenesis of atherosclerosis and calcific aortic valve disease. There are currently no therapies available in clinical practice that selectively lower Lp(a) levels. In the…

Upfront Combination Therapy for LDL-C Lowering in Acute Coronary Syndrome: The Rule Rather than the Exception? Open

A. Bate, Peter J. Psaltis, Stephen J. Nicholls, Adam J. Nelson · 2025

Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS Open

Masashi Fujino, Giuseppe Di Giovanni, Julie Butters Bhsc, Yu Kataoka, Thomas Hucko , et al. · 2025

NCT03570697.

Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy Open

Stephen J. Nicholls, Adam J. Nelson · 2025

Purpose of Review The use of statins has transformed approaches to the prevention of cardiovascular disease. However, many patients remain at a major risk of experiencing cardiovascular events, due to a range of factors including suboptima…

Learnings from Implementation Strategies to Improve Lipid Management Open

N. Lan, Ruofei Chen, Girish Dwivedi, Gerald F. Watts, Stephen J. Nicholls , et al. · 2025

Defining, measuring, and addressing medication non-adherence in cardiovascular disease Open

Adam Livori, Lachlan L. Dalli, Stephen J. Nicholls, Adam J. Nelson · 2024

Polygenic Prediction of Recurrent Events After Early-Onset Myocardial Infarction Open

Maddalena Ardissino, Elvezia Maria Paraboschi, Samuel A. Lambert, Lois G. Kim, Martin Kelemen , et al. · 2024

BACKGROUND: Myocardial infarction (MI) is a complex disease caused by both lifestyle and genetic factors. This study aims to investigate the predictive value of genetic risk, in addition to traditional cardiovascular risk factors, for recu…

Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non‐human primate studies and clinical trials Open

Stephen J. Nicholls, Adam J. Nelson, John J.P. Kastelein, Marc Ditmarsch, Andrew Hsieh , et al. · 2024

Anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor previously under development, exhibited an usually extended terminal half‐life and large food effect and accumulated in adipose tissue. Other CETP inhibitors have not shown…

Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future Open

James P. Psaltis, J. Marathe, Mau T. Nguyen, Richard Le, Christina A. Bursill , et al. · 2024

Among newer classes of drugs for type 2 diabetes mellitus (T2DM), glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) are incretin‐based agents that lower both blood sugar levels and promote weight loss. They do so by activating pancreat…

Cardiology patients are unaware of the benefits of seasonal influenza immunization Open

Sarah R. Monagle, E. Spear, Timothy Abrahams, Udit Thakur, D. Pol , et al. · 2024

Despite guideline recommendations, most cardiology patients are uninformed of the cardiovascular benefits of seasonal influenza immunization with many unaware they are at higher risk of influenza-related illness. The vast majority of patie…

Computed tomography coronary angiography assessment of left main coronary artery stenosis severity Open

Udit Thakur, Jason Nogic, Andrea Comella, Nitesh Nerlekar, Jasmine Chan , et al. · 2024

CTCA derived MLA and MLD have a strong correlation with IVUS. A CTCA derived MLA cut-off <8.29 mm² showed greatest clinical utility for predicting the need for further assessment, based on IVUS gold standard.

Patterns of 12-Month Post-Myocardial Infarction Medication Use According to Revascularisation Strategy: Analysis of 15,339 Admissions in Victoria, Australia Open

Adam Livori, Zanfina Ademi, Jenni Ilomäki, Adam J. Nelson, J. Simon Bell , et al. · 2024

Post-discharge dispensing of secondary prevention medications differed with respect to revascularisation strategy from 2012 to 2017, despite clear evidence of benefit during this period. Interventions may be needed to address possible clin…

Cancer Screening in Patients with Heart Failure with Mildly Reduced and Reduced Ejection Fraction Open

Sean Tan, Grace JX Chung, Jasmine Chan, S. Lockwood, Rahul G. Muthalaly , et al. · 2024

Background: Heart failure with mildly reduced and reduced ejection fraction are associated with incident cancer. However, cancer screening is not routinely discussed in this population. This study aimed to describe the uptake and perceptio…

Machine-Learning for Phenotyping and Prognostication of Myocardial Infarction and Injury in Suspected Acute Coronary Syndrome Open

Ehsan Khan, Kristina Lambrakis, Zhibin Liao, Joey Gerlach, Tom Briffa , et al. · 2024

Machine learning models can digitally phenotype suspected ACS patients at index presentation and predict subsequent events within 30 days. These models require external validation in a randomized clinical trial to evaluate their impact in …

Letter to the Editor: Lipid-lowering therapy in patients with a ‘normal’ LDL-C Open

John C. Hackett, Adam J. Nelson, Stephen J. Nicholls · 2024

Lipid-lowering therapy in patients with a 'normal' LDL-CThank you for the valuable article on managing hypercholesterolaemia. 1 Given there is no target lipid concentration for reducing cardiovascular disease risk, in a patient at high car…

Variation of computed tomography-derived extracellular volume fraction and the impact of protocol parameters: A systematic review and meta-analysis Open

Rahul G. Muthalaly, Sean Tan, Adam J. Nelson, Timothy Abrahams, Donghee Han , et al. · 2024

CT-ECV estimates for healthy individuals vary widely in the literature and there is significant overlap with estimates in cardiac disease. One quarter of this heterogeneity is explained by differences in CT-ECV protocol parameters. Standar…

Cardiovascular risk in cancer patients treated with immune checkpoint inhibitors: challenges and future directions Open

Sean Tan, Adam J. Nelson, Rahul G. Muthalaly, Satish Ramkumar, Joshua W. Hamilton , et al. · 2024

Cardiovascular disease is the leading cause of non-cancer related mortality and morbidity among people living with or cured from cancer. Immune checkpoint inhibitors (ICIs) are systemic anti-cancer therapies that have revolutionized the tr…

Obesity in the Asia-Pacific Region: Current Perspectives Open

David Tak Wai Lui, Junya Ako, Jamshed Dalal, Alan Yean Yip Fong, Masashi Fujino , et al. · 2024

Obesity has become a pandemic in the Asia-Pacific region, with an alarming rate of increase in the prevalence of obesity. The impact of obesity and its associated comorbidities goes beyond the healthcare system, posing a substantial burden…

Adam J. Nelson YOU? Author Swipe